• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Defining low-risk lesions in early-stage esophageal adenocarcinoma.定义早期食管腺癌中的低风险病变。
J Thorac Cardiovasc Surg. 2021 Oct;162(4):1272-1279. doi: 10.1016/j.jtcvs.2020.10.138. Epub 2020 Nov 24.
2
Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review.内镜及手术切除 T1a/T1b 食管肿瘤:系统评价。
World J Gastroenterol. 2013 Mar 7;19(9):1424-37. doi: 10.3748/wjg.v19.i9.1424.
3
Predictors of Nodal Metastases for Clinical T2N0 Esophageal Adenocarcinoma.临床 T2N0 食管腺癌淋巴结转移的预测因素。
Ann Thorac Surg. 2018 Jul;106(1):172-177. doi: 10.1016/j.athoracsur.2018.02.087. Epub 2018 Apr 5.
4
Using the National Cancer Database to create a scoring system that identifies patients with early-stage esophageal cancer at risk for nodal metastases.利用国家癌症数据库创建一个评分系统,以识别早期食管癌患者中存在淋巴结转移风险的患者。
J Thorac Cardiovasc Surg. 2017 Nov;154(5):1787-1793. doi: 10.1016/j.jtcvs.2017.07.036. Epub 2017 Jul 29.
5
Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: implications for endoscopic treatment.T1期食管癌的多灶性肿瘤形成和淋巴结转移:对内镜治疗的影响
Ann Surg. 2008 Mar;247(3):434-9. doi: 10.1097/SLA.0b013e318163a2ff.
6
Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens.内镜治疗是否适用于表浅型黏膜下食管腺癌?食管切除术标本的分析。
J Am Coll Surg. 2010 Apr;210(4):418-27. doi: 10.1016/j.jamcollsurg.2010.01.003.
7
Surgical Management of Early-Stage Esophageal Adenocarcinoma Based on Lymph Node Metastasis Risk.基于淋巴结转移风险的早期食管腺癌的外科治疗。
Ann Surg Oncol. 2018 Jan;25(1):318-325. doi: 10.1245/s10434-017-6238-z. Epub 2017 Nov 16.
8
Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.内镜下切除黏膜下食管鳞癌后行食管切除术与放化疗的长期疗效比较。
Dis Esophagus. 2019 Dec 31;32(12). doi: 10.1093/dote/doz023.
9
Predicting lymph node metastases in early esophageal adenocarcinoma using a simple scoring system.利用简单评分系统预测早期食管腺癌的淋巴结转移。
J Am Coll Surg. 2013 Aug;217(2):191-9. doi: 10.1016/j.jamcollsurg.2013.03.015. Epub 2013 May 6.
10
The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens.T1 期食管腺癌患者淋巴结转移的患病率:食管切除术标本的回顾性分析。
Ann Surg. 2011 Feb;253(2):271-8. doi: 10.1097/SLA.0b013e3181fbad42.

本文引用的文献

1
Surveillance Implications of Recurrence Patterns in Early Node-Negative Esophageal Adenocarcinoma.早期淋巴结阴性食管腺癌复发模式的监测意义。
Ann Thorac Surg. 2019 Dec;108(6):1640-1647. doi: 10.1016/j.athoracsur.2019.05.066. Epub 2019 Jul 16.
2
Trends in Treatment of T1N0 Esophageal Cancer.T1N0 期食管癌的治疗趋势。
Ann Surg. 2019 Sep;270(3):434-443. doi: 10.1097/SLA.0000000000003466.
3
A Clinical Nomogram for Predicting Node-positive Disease in Esophageal Cancer.用于预测食管癌淋巴结阳性疾病的临床列线图
Ann Surg. 2021 Jun 1;273(6):e214-e221. doi: 10.1097/SLA.0000000000003450.
4
Ongoing Challenges with Clinical Assessment of Nodal Status in T1 Esophageal Adenocarcinoma.T1 食管腺癌淋巴结状态临床评估的持续挑战。
J Am Coll Surg. 2019 Oct;229(4):366-373. doi: 10.1016/j.jamcollsurg.2019.04.032. Epub 2019 May 17.
5
What Constitutes Optimal Management of T1N0 Esophageal Adenocarcinoma?T1N0 食管腺癌的最佳治疗方法是什么?
Ann Surg Oncol. 2019 Mar;26(3):714-731. doi: 10.1245/s10434-018-07118-5. Epub 2019 Jan 3.
6
The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis.内镜监测对巴雷特食管患者的影响:系统评价和荟萃分析。
Gastroenterology. 2018 Jun;154(8):2068-2086.e5. doi: 10.1053/j.gastro.2018.02.022. Epub 2018 Feb 16.
7
Esophagectomy versus endoscopic resection for patients with early-stage esophageal adenocarcinoma: A National Cancer Database propensity-matched study.食管切除术与内镜下切除术治疗早期食管腺癌患者的效果比较:一项基于国家癌症数据库的倾向评分匹配研究。
J Thorac Cardiovasc Surg. 2018 May;155(5):2211-2218.e1. doi: 10.1016/j.jtcvs.2017.11.111. Epub 2018 Jan 31.
8
Endoscopic ultrasound staging for early esophageal cancer: Are we denying patients neoadjuvant chemo-radiation?内镜超声分期在早期食管癌中的应用:我们是否拒绝了患者新辅助放化疗?
World J Gastroenterol. 2017 Dec 14;23(46):8193-8199. doi: 10.3748/wjg.v23.i46.8193.
9
Surgical Management of Early-Stage Esophageal Adenocarcinoma Based on Lymph Node Metastasis Risk.基于淋巴结转移风险的早期食管腺癌的外科治疗。
Ann Surg Oncol. 2018 Jan;25(1):318-325. doi: 10.1245/s10434-017-6238-z. Epub 2017 Nov 16.
10
Treatment allocation in patients with early-stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement.早期食管腺癌患者的治疗分配:淋巴结受累的患病率及预测因素
Cancer. 2016 Jul 15;122(14):2150-7. doi: 10.1002/cncr.30040. Epub 2016 May 3.

定义早期食管腺癌中的低风险病变。

Defining low-risk lesions in early-stage esophageal adenocarcinoma.

作者信息

Sihag Smita, De La Torre Sergio, Hsu Meier, Nobel Tamar, Tan Kay See, Gerdes Hans, Shah Pari, Bains Manjit, Jones David R, Molena Daniela

机构信息

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

出版信息

J Thorac Cardiovasc Surg. 2021 Oct;162(4):1272-1279. doi: 10.1016/j.jtcvs.2020.10.138. Epub 2020 Nov 24.

DOI:10.1016/j.jtcvs.2020.10.138
PMID:33334599
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8141543/
Abstract

OBJECTIVE

As endoscopic approaches become more widely used to treat early-stage esophageal cancer, reliably identifying patients with less-aggressive tumors is paramount. We sought to identify risk factors for recurrence in patients with completely resected T1 esophageal adenocarcinoma.

METHODS

We retrospectively analyzed a single-institutional database for all patients with completely resected pathologic T1 esophageal adenocarcinoma (1996-2016). Risk factors for recurrence were identified using competing-risk regression methods. Risk stratification was performed on the basis of known preoperative clinicopathologic factors; this model's discriminative power for overall survival was evaluated using a Cox proportional hazards model.

RESULTS

Of 243 patients, 32 experienced recurrence. At a median follow-up among survivors of 4 years (range, 0.05-19 years), the 5-year cumulative incidence of recurrence was 15%, and median time to recurrence was 2 years (range, 0.26-6.13 years). On univariable analysis, submucosal invasion, N1 disease, poor differentiation, tumor length, lymphovascular invasion, and multicentricity were significantly associated with recurrence. On multivariable analysis, N1 disease (hazard ratio, 2.93; 95% confidence interval, 1.17-7.34; P = .022) and tumor length (hazard ratio, 1.44; 95% confidence interval, 1.12-1.86; P = .004) were independently associated with recurrence. Risk stratification showed that patients without lymphovascular invasion and a with median tumor length of 0.8 cm (range, 0.10-1.70 cm) had a <10% risk of recurrence and improved survival.

CONCLUSIONS

Pathologic T1 tumors have a 5-year cumulative incidence of recurrence of 15%. Nodal involvement and tumor length were independent risk factors for recurrence, whereas tumors <2 cm in length without lymphovascular invasion were associated with a low risk of recurrence.

摘要

目的

随着内镜治疗方法越来越广泛地用于治疗早期食管癌,可靠地识别肿瘤侵袭性较小的患者至关重要。我们试图确定完全切除的T1期食管腺癌患者复发的危险因素。

方法

我们回顾性分析了一个单机构数据库中所有完全切除的病理T1期食管腺癌患者(1996 - 2016年)的数据。使用竞争风险回归方法确定复发的危险因素。根据已知的术前临床病理因素进行风险分层;使用Cox比例风险模型评估该模型对总生存的判别能力。

结果

243例患者中,32例出现复发。在幸存者的中位随访时间为4年(范围0.05 - 19年)时,5年累积复发率为15%,复发的中位时间为2年(范围0.26 - 6.13年)。单因素分析显示,黏膜下侵犯、N1期疾病、低分化、肿瘤长度、脉管侵犯和多中心性与复发显著相关。多因素分析显示,N1期疾病(风险比,2.93;95%置信区间,1.17 - 7.34;P = 0.022)和肿瘤长度(风险比,1.44;95%置信区间,1.12 - 1.86;P = 0.004)与复发独立相关。风险分层显示,无脉管侵犯且肿瘤中位长度为0.8 cm(范围0.10 - 1.70 cm)的患者复发风险<10%,生存情况改善。

结论

病理T1期肿瘤的5年累积复发率为15%。淋巴结受累和肿瘤长度是复发的独立危险因素,而长度<2 cm且无脉管侵犯的肿瘤复发风险较低。